Back to Peptides

CJC-1295

Growth Factors & Muscle Building

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed with a longer half-life to support prolonged GH secretion in research settings. It is studied for its pharmacokinetic improvements over natural GHRH, especially when combined with GHRP peptides. The DAC modification allows for extended half-life and reduced injection frequency while significantly elevating IGF-1 levels.

Reconstitute
3 mL BAC + 2mg vial
7 mcg/unit
Daily Range
50–150 mcg Subcutaneous (SQ)
2-3 times daily (typically before meals or at bedtime)
Standard Dose
100 mcg
Cycle
4–8 weeks
then reassess
CJC-1295GHRH analoggrowth hormoneIGF-1muscle growthfat reduction

Dosing & Reconstitution Guide

In human research settings, CJC-1295 with DAC has been administered at 1–2 mg per week. These doses were used in tightly controlled environments. It is not approved for general use.

Standard / Gradual Approach

standard
PhaseDoseVolume
Week 1500mcg
Week 2500mcg
Week 31000mcg
Week 41000mcg

Protocol Summary

Subcutaneous (SQ): 2-3 times daily (typically before meals or at bedtime) · Dose range 50150 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

CJC-1295 DAC: 500 mcg 1–2x per week. CJC-1295 no DAC: 50-150 mcg before bed or post-workout for 5 days on 2 days off. Recommended cycle: 8–12 weeks with equal time off.

🧪 Quick Start

BAC Water
3 mL

Potential Benefits & Use Cases

CJC-1295 is a research compound not approved by the FDA for any medical purpose. All studies referenced were conducted in animals or clinical research volunteers under supervision
Produces sustained 2–10 fold GH elevation and 1.5–3 fold IGF-1 elevation in a dose-dependent manner (human trial)
May promote increased lean body mass, reduced fat mass, and improved body composition (preclinical)
Enhances protein synthesis and recovery potential through anabolic signaling (preclinical)
May support deeper sleep through GHRH's documented role in sleep architecture (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

GHRH receptor agonist
Stimulates growth hormone secretion
Extends pulsatile GH release via DAC binding to albumin

Lifestyle & Optimization

timing

Inject 2–3x daily, ideally before bed and post-workout.

diet

Adequate protein (0.8–1g per pound body weight) and complex carbohydrates.

exercise

Regular resistance training 4–5 times per week.

sleep

Consistent sleep schedule with 7–9 hours nightly — GHRH is most effective during sleep.

Side Effects & Safety

Common Side Effects

Transient flushing, headache, or water retention during initial titration

🧮 Dose Calculator

Concentration
6.7
mcg/unit
Draw Volume
75
units (0.750 mL)
For a 500 mcg dose, draw 75 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High bioavailability due to slow-release design; once or twice weekly dosing effective
Oral Administration
Unavailable due to first-pass degradation
Half-Life
6–8 days with DAC (versus 30 minutes without)
Degradation
Slow enzymatic breakdown via albumin-binding system
Tissue Specificity
Targets pituitary somatotrophs to stimulate pulsatile GH secretion
⚗️

Peptide Details

Molecular Weight
3647.2
Formula
C165H269N47O46
Sequence
Modified GHRH sequence with DAC
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
Store lyophilized powder at room temperature (18-25°C) before reconstitution, then refrigerate at 2-8°C
Reconstituted (Mixed)
After reconstitution, . Reconstituted solution is stable for 30 days when properly stored.